Underestimation (%) | IGTVMIP | IGTV2Phases | IGTVMIP-Modified | |
---|---|---|---|---|
Stage I patients | Â | Â | Â | Â |
 | Avg. ± SD | 17.33 ± 6.56 | 19.32 ± 5.93 | 5.36 ± 1.71 |
 | Range | 6.32–30.86 | 6.03–31.76 | 2.30–8.53 |
Stage III patients | Â | Â | Â | Â |
 | Avg. ± SD | 12.11 ± 6.23 | 8.95 ± 5.15 | 4.21 ± 1.66 |
 | Range | 4.04–23.85 | 4.01–22.25 | 1.20–6.66 |
Overestimation (%) | IGTVMIP | IGTV2Phases | IGTVMIP-Modified | |
Stage I patients | Â | Â | Â | Â |
 | Avg. ± SD | 3.23 ± 2.35 | 0 | 4.80 ± 2.39 |
 | Range | 0.34–8.64 | 0 | 1.30–10.07 |
Stage III patients | Â | Â | Â | Â |
 | Avg. ± SD | 2.36 ± 1.79 | 0 | 3.21 ± 2.22 |
 | Range | 1.06–6.92 | 0 | 1.43–8.09 |